Form 4: Neumora Therapeutics Executive Daljit Singh Aurora Reports Stock Option Transfers to Family Trust
SEC Form 4
Daljit Singh Aurora, Chief Strategy Officer of Neumora Therapeutics, reports the transfer of fully vested stock options to the Aurora Family Trust.
Summary
- On September 12, 2024, Daljit Singh Aurora, Chief Strategy Officer of Neumora Therapeutics, filed a Form 4.
- The filing reports the transfer of fully vested stock options to the Aurora Family Trust.
- These options include rights to buy common stock at prices of $4.24, $6.51, and $6.36.
- The transferred options have expiration dates in 2031 and 2033.
- Aurora directly owns 97,500 shares of common stock and indirectly owns 114,703 shares through the Aurora Family Trust.
- Aurora directly owns 40,890, 207,901 and 72,221 stock options and indirectly owns 137,538, 136,210 and 29,737 stock options through the Aurora Family Trust.
Sentiment
Score: 5
Explanation: This is a neutral filing related to standard executive compensation and estate planning. It doesn't inherently indicate positive or negative sentiment regarding the company's performance.
Positives
- The transfer of vested stock options to a family trust is a common estate planning strategy.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates internal transactions related to stock options.
Comparison to Industry Standards
- Stock option grants and transfers are a common form of compensation and wealth management for executives in publicly traded companies like Neumora Therapeutics.
- Similar transactions are regularly reported by executives at comparable pharmaceutical and biotechnology firms such as Biogen, Eli Lilly, and Pfizer.
Related Party Transactions
- The transfer of stock options to the Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries, constitutes a related party transaction.
Stakeholder Impact
- The transaction itself has minimal direct impact on stakeholders.
- It reflects internal management of personal assets by an executive.
Key Dates
| Date | Description |
|---|---|
| 08/02/2021 | Vesting Commencement Date for some stock options. |
| 02/01/2023 | Vesting Commencement Date for some stock options. |
| 06/22/2023 | Vesting Commencement Date for some stock options. |
| 09/12/2024 | Date of transaction and filing of Form 4. |
| 09/13/2024 | Date of signature. |
| 09/20/2031 | Expiration date for some stock options. |
| 01/18/2033 | Expiration date for some stock options. |
| 06/22/2033 | Expiration date for some stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.